Mauro Chiarito
@ChiaritoMauro
Followers
121
Following
330
Media
0
Statuses
21
In the HELP-HF registry, a higher number of "I NEED HELP" criteria was associated with a worse prognosis, with specific individual criteria having an independent prognostic impact @MarcoMetra @contessi_AHA @ChiaritoMauro #AHAJournals
https://t.co/x7dVKBkkju
0
8
24
DCB vs. DES for LAD PCI. A Featured Science Presentation @CRF #TCT2023 published simultaneously in https://t.co/XGSRacYI3Y.
https://t.co/YQD8yvwxVx
@mauro_gitto @Sticchi_Alex @ChiaritoMauro @Antocol17 #TCTConference #ACCFIT #AHAJournals
0
34
86
🌟Exciting #PhD Positions at Humanitas University, Milan! 🌟 Join our cutting-edge #research team and explore the world of #platelets and #DataScience in medicine. We're offering 2 exceptional #PhD positions: 1️⃣ Molecular & Experimental #Medicine 2️⃣ Data Science in Medicine
1
4
8
What is your practice with metformin before coronary angiography? Take a look at the results of this multicenter study on the safety of metformin continuation in patients undergoing coronary angiography
Safety of metformin continuation in diabetic patients undergoing ICA: no increase in lactate levels, no decline in renal function. https://t.co/dIoa9IMwBh
@ChiaritoMauro @sjorge4 @piccoloraf @gcondorelli @Drroxmehran @hect2701
0
2
12
I somari mi rinfacciano questo tweet del settembre 2021 come errato. Invece è correttissimo: il primo antivirale (Molnupiravir) da utilizzare per la cura precoce di COVID è stato autorizzato nel novembre 2021 e per le altre malattie è valido tuttora quanto scritto.
3
14
369
Small vessel CAD: critical appraisal of the literature and proposed definition ⚠️ <2.5 mm 🔗 https://t.co/vo27qWCVdZ
@hect2701 @JL_10_HILL @ron_waksman @ChiaritoMauro @GauravGillMD
How Small is Small? We propose a reference vessel diameter <2.5 mm as the definition of small vessel #CAD in order to guide future clinical trials and clinical decision making. ➡️ https://t.co/DBUYI53XJ8
@sjorge4 @hect2701 @ron_waksman @ChiaritoMauro @GauravGillMD @JL_10_HILL
0
3
10
🫀Evolution of drug-eluting coronary stents: a back-and-forth journey from the bench-to-bedside @Drroxmehran @CaoDavide @JohnyNicolas @ChiaritoMauro @capivato @FBeerkens #CardioEd #Cardiology @torresviera @CVR_TomaszGuzik @mencardio @Serginho1409
1
43
84
🧩 Enjoy a 📖 on Prognostic Value of #TR on #ValveDiseaseDay 2/22/22 #Tricuspid ☘️ #PCRTricuspid #treatTR #CardioTwitter #MedEd @valvediseaseday
https://t.co/Zm9iMyeak8
@RCMjournal
@AntonioMangieri @ChiaritoMauro @azeemlatib @DamianoRegazzo1 @Antocol17 @GGStefanini
0
5
11
The ARC-HBR definition is prognostic for males and females, despite sex-related differences in the prevalence and bleeding risk associated with individual #HBR criteria. @DrMatteoNardin @Drroxmehran @MountSinaiHeart @CircIntv
ahajournals.org
Graphical Abstract Background: Bleeding events after percutaneous coronary intervention are associated with substantial morbidity and mortality. Female patients undergoing percutaneous coronary...
0
2
13
Considering the trial findings, "will clopidogrel replace aspirin for secondary prevention of cardiovascular disease in clinical practice?" Read the linked Comment by @ChiaritoMauro and @GGStefanini: https://t.co/wtH8LD3n7i.
0
8
14
0
2
2
"in all affairs it is a healthy thing now and then to hang a question mark on the things you have long taken for granted" Just published in @TheLancet!
#Clopidogrel vs #Aspirin for secondary #cardiovascular prevention. We should constantly critically review our standard of care! Today in @TheLancet HOST-EXAM trial https://t.co/2Md5Hao27X Comment https://t.co/IieZQnQOsf
@ChiaritoMauro
0
0
9
Updated meta-analysis of 31 trials (n=30,096): #RadialFirst a/w less bleeding, vascular complications, & mortality than femoral access for coronary angio & PCI. https://t.co/ZRQxpN6Hcd
@MountSinaiHeart Follow @CCIJournal, https://t.co/oEQYGH7lGw Official Journal of @SCAI
3
20
38
Published today in @JACCJournals our study evaluating the echocardiographic abnormalities of hospitalized patients with Covid-19 and myocardial injury. Incredible collaboration in the middle of the pandemic between NYC and Milan hospitals. @GGStefanini
https://t.co/kpi29fwoO4
3
20
97
Perché è importante che ci sia Il Post. Perché se ho un sito di meteo e scrivo che domani piove ho cento click. Se scrivo che diluvia ne ho mille. https://t.co/QCwA5K9Iwu
ilpost.it
Oggi facciamo tamponi a categorie diverse di persone e la situazione negli ospedali è straordinariamente cambiata, tra le altre cose
47
344
2K
Pragmatic strategy to optimize risk stratification in #COVID19: early systematic assessment of #troponin and #BNP at the time of hospital admission @ChiaritoMauro @FrancescoC90 @gcondorelli @HumanitasMilano @HUNIMED @Heart_BMJ
0
11
22
Our BEAT registry on #circInterventions comparing Sapien 3 vs @Medtronic EvolutR/Pro in BAV. Thanks to all the co-authors for their great work and efforts @didier_tchetche @azeemlatib @GalloFrance87 @DamianoRegazzo1 @ChiaritoMauro
Balloon Versus Self-Expanding Valve for Treatment of Bicuspid Aortic Valve Stenosis. Insight from the BEAT Registrys by @AntonioMangieri and colleagues ➡️ Similar success with ⬆️ Annular rupture versus paravalvular aortic regurgitation https://t.co/JsNNE6VIqV
#AHAJournals #TAVR
0
4
20
DCB vs DES for small CAD DCB associated with similar TVR and restenosis and lower risk of vessel thrombosis DES implantation yields slightly better angiographic surrogate endpoints @ChiaritoMauro @GGStefanini @CCIJournal
DCB vs. DES for small coronary artery disease: meta‐analysis. Similar TVR, TLR, all-cause mortality; lower vessel thrombosis w/ DCB (OR 0.12). https://t.co/dyidvwpWBF Follow @CCIJournal, https://t.co/oEQYGH7lGw Official Journal of @SCAI
1
4
13
#COVID19 patients who continue ACEi/ARBs have a lower mortality vs. those discontinuing or not taking ACEi/ARBs at home, suggesting that ACEis/ARBs could have a therapeutic role in #COVID19 @FrancescoC90 @GGStefanini #ESC_Journals
https://t.co/mYaQRgO4zN
0
0
7
P2Y12-inhibitor monotherapy reduces risk of MI compared to #aspirin for secondary #cardiovascular #prevention. However, high NNT and absence of any impact on mortality question the clinical relevance of this benefit. @ChiaritoMauro @sjorge4 @TheLancet
https://t.co/SuJEUeiiJY
2
5
26